Navigation Links
Vystar Corporation Engages The Investor Relations Group
Date:2/3/2010

ATLANTA, Feb. 3 /PRNewswire-FirstCall/ -- Vystar® Corporation (OTC Bulletin Board: VYST), the creator of Vytex® Natural Rubber Latex (NRL), a patented, all-natural raw material that significantly reduces antigenic proteins found in natural rubber latex, has engaged The Investor Relations Group ("IRG"), a thirteen-year-old, award-winning, corporate communications firm based in New York City, to serve as its investor relations and public relations agency.

(Logo: http://www.newscom.com/cgi-bin/prnh/20100203/CL48049LOGO)

IRG's investor relations team will target specific portfolio managers and equity analysts in the global investment community to increase awareness of Vystar's natural rubber latex product, Vytex NRL. Concurrent with that effort, the public relations team will initiate an outreach campaign targeting editors, writers, and segment producers of local and national trade and consumer online, print, radio, and broadcast media outlets worldwide.

"Vystar has aggressive plans for 2010, and we are confident that IRG will have a great story to tell to the investment community and the media at large," commented Bill Doyle, Chairman and Chief Executive Officer.  "We are proud that Vytex NRL has been approved in its first commercial product, the Envy™ Ultra Thin condom, with labeling allowed by the FDA that indicates a level of antigenic protein of less than two micrograms/dm2.  Additionally, we have several companies evaluating Vytex NRL for use in their products, including various adhesive applications, foam mattresses and pillows, balloons and gloves.  We look forward to working with IRG as we achieve our objectives and will update the investment community as we move ahead."

IRG's corporate communications program includes new media and multimedia initiatives that involve the creation of broadcast-ready corporate videos, podcasts, and the creation of social networking, video service, and micro-blogging accounts. The Investor Relations Group was recently honored with a "Stevie Award" for Investor Relations Program of the Year and named a finalist in the Best Media Website category from the 2009 American Business Awards.

About Vystar Corporation

Based in Duluth, Ga., Vystar Corporation (OTC BB: VYST.OB) is the creator of Vytex® Natural Rubber Latex (NRL), a patented, all-natural raw material that significantly reduces antigenic proteins found in the over 40,000 products made with natural rubber latex and that are believed to cause latex allergies. The first product made with Vytex® NRL, the Envy™ Ultra Thin condom, which is manufactured by Alatech Healthcare LLC of Eufaula, Alabama, was introduced to the US market in 2009. This product gives the consumer first-hand experience with the remarkable benefits of Vytex NRL.  In addition to the condom market, Vystar is working with manufacturers across a broad range of consumer and medical products to bring Vytex NRL to market in adhesives, surgical and exam gloves, and natural rubber latex foam mattresses, pillows and sponges.  For more information, visit www.vytex.com.

About The Investor Relations Group, Inc.

The Investor Relations Group, Inc. (IRG) offers a full-service corporate communications program designed to suit the many unique needs of Alternative Public Offering (APO) companies. The program utilizes a proprietary, targeted approach to reach institutional investors, analysts, and the media-at-large. For further information, please visit the company's website at http://www.investorrelationsgroup.com.

Forward-looking Statements: Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Actual results may differ materially from those included in these statements due to a variety of factors.  More information about these factors is contained in Vystar's filings with the Securities and Exchange Commission.

SOURCE Vystar Corporation

RELATED LINKS
http://www.vytex.com

'/>"/>

SOURCE Vystar Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Techne Corporation Declares Dividend
2. ETEX Corporation Announces Distribution Agreement With OrthoPediatrics Corp.
3. Laerdal Medical and Medical Simulation Corporation Partner to Offer Integrated Training Courses for SimMan(R) Patient Simulators
4. Providence Service Corporation to Present at the Sidoti & Company, LLC Micro Cap Conference on Monday, January 11th and at the CJS Securities New Ideas for the New Year Conference on Thursday, January 14th
5. LOREAL and Hurel Corporation Announce R&D Collaboration to Develop a Non-Animal Alternative, Microfluidic Biochip
6. Stryker Corporation Announces Pricing of Senior Notes
7. CVS Caremark Corporation Increases Quarterly Dividend 15%
8. Volcano Corporation Announces Preliminary Record Revenues for Fourth Quarter 2009; Total Year Revenues are Expected to Exceed Prior Guidance
9. Somanetics Corporation to Release Fourth Quarter and Fiscal 2009 Financial Results and Host Conference Call January 21, 2010
10. Colorado-Based Spectranetics Corporation to Pay $5 Million to Resolve Allegations Relating to its Medical Devices
11. Baxa Corporation to Sponsor Free Culture of Safety Webinar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 4, 2016 Frontier Pharma: Chronic Obstructive ... Innovation Chronic Obstructive Pulmonary Disease ... inflammation of the airways and lungs. Persistent breathing ... the disease one of the leading causes of ... the world. COPD is linked to cumulative exposure ...
(Date:2/4/2016)... Feb. 4, 2016  Aethlon Medical, Inc. (Nasdaq: ... biofiltration devices to treat life-threatening diseases, today announced ... ended December 31, 2015. --> ... set forth in our last quarterly call, we ... our long-term objective to establish the Aethlon Hemopurifier® ...
(Date:2/4/2016)...  Blueprint Medicines Corporation (NASDAQ: BPMC ), ... investigational kinase medicines for patients with genomically defined ... of directors of Lonnel Coats , a ... industry-related experience. Jeffrey Albers , ... strategic experience developing and commercializing numerous oncology products ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... February 06, 2016 , ... Shark Finds ... the launch of a new DRTV campaign with Belly Bands. , Having a dog ... from sprays to puppy pads and find nothing works, get Belly Bands, the ...
(Date:2/5/2016)... Toronto, Ontario (PRWEB) , ... February 05, 2016 ... ... today announced the availability of the company's lighter, sleeker next generation LYNX VR ... assembly plant. , Improvements in design and manufacturing not only reduce the ...
(Date:2/5/2016)... ... 05, 2016 , ... The Muscular Dystrophy Association and Sailormen ... the 14th annual “Appetite for a Cure” campaign on Feb. 1 to raise ... related diseases that severely limit strength and mobility. , Now through March ...
(Date:2/5/2016)... ... 05, 2016 , ... After years as an active staff surgeon and having ... surgeon Dr. Wayne Carman transitioned to chief of the Division of Plastic Surgery at ... term as chief and began a second three-year term in January of 2016. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... The American public tends to ... may be safer than regular municipal or well water. The recent experience with lead ... Kleyne, could go a long way toward increasing public acceptance of recycled waste water ...
Breaking Medicine News(10 mins):